The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation
Fan Luo(Tongren Hospital), Hongyun Zhao(Sun Yat-sen University)
Cited by 65
Related Papers
Myeloid-derived itaconate suppresses cytotoxic CD8+ T cells and promotes tumour growth
|Nature Metabolism|2022|155
Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
|Journal for ImmunoTherapy of Cancer|2019|103
A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial
|Nature Medicine|2025|76
Evaluation of Safety of Treatment With Anti–Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors
|JAMA Oncology|2022|69
A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors
|Cancer Communications|2020|54